Upstream Bio, Inc.

NASDAQ:UPB

Biotechnology

Healthcare
$2.08 +1.63%

+$0.10 today

Market cap
$114.01M
Beta
1.11
P/E (TTM)
-2.2
EPS (TTM)
-$2.89
52W Low $5.85High $33.68

Volume 1.24M

Average 0.66M

UPB Pre-Tax Margin

Income before tax as a percentage of revenue.

Upstream Bio, Inc.NASDAQ: UPB

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin widens to -3925.6%

Pre-tax margin was -3925.6% in Q1 FY2026, up 892.4 pp from a year earlier. On a trailing-twelve-month basis it was -4719.0%, down 1270.3 pp year over year. Over 3 fiscal years it narrowed by 3056.7 pp.

Context

  • Pre-tax margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-3925.6%+2430.5 pp QoQ
Last fiscal yearDec 2025
-5026.0%-2376.0 pp YoY
LTMMar 2026
-4719.0%-1270.3 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+892.4 pp——
1 year-2376.0 pp——
3 years-3056.7 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-5026.0%
Year-over-year change
-2376.0pp

Pre-Tax Margin vs competitors

How UPB compares with its peers on the latest reported figures

  • UPB's LTM Mar 2026 pre-tax margin of -4719.0% is the lowest of the 8 companies compared; the peer median is -291.6%.
  • Its year-over-year change of -1270.3 pp is the lowest of 7, against a peer median of +251.8 pp.
  • Over three fiscal years its change of -3056.7 pp compares with a peer median of +2118.8 pp.
UPB Competitors Peer median
Pre-Tax Margin for UPB and competitors
Company Period LTM level YoY 3-year change
NVAXNovavax, Inc.LTM Mar 2026-14.5% -53.4 pp+80.2 pp
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-112.0% +645.5 pp—
WVEWave Life Sciences Ltd.LTM Mar 2026-255.7% -148.7 pp+3937.7 pp
SYRESpyre Therapeutics, Inc.LTM Sep 2026-291.6% ——
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-597.0% +557.1 pp+299.9 pp
RLAYRelay Therapeutics, Inc.LTM Jun 2026-2763.6% +964.8 pp+19235.6 pp
ZBIOZenas BioPharma, Inc.FY2025-3778.2% -647.0 pp—
UPBUpstream Bio, Inc.LTM Mar 2026-4719.0% -1270.3 pp-3056.7 pp
AMLXAmylyx Pharmaceuticals, Inc.FY2025— ——
PHVSPharvaris N.V.FY2025— ——
Peer median (excluding UPB) -291.6%+251.8 pp+2118.8 pp

Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.21M2.38M2.37M2.85M
Cost of Revenue0000
Gross Profit1.21M2.38M2.37M2.85M
Gross Margin100.0%100.0%100.0%100.0%
Research & Development18.66M31.8M62.97M136.81M
Selling, General & Admin6.46M10.7M17.17M26.41M
Operating Expenses25.12M42.49M80.13M163.22M
Depreciation & Amortization7K60K89K188K
EBITDA(23.86M)(20.48M)(62.72M)(143.26M)
EBITDA Margin-1968.7%-860.4%-2646.3%-5019.4%
Operating Income(23.91M)(40.11M)(77.76M)(160.36M)
Operating Margin-1972.7%-1685.5%-3281.2%-5618.8%
Interest Income205K4.17M12.12M16.93M
Interest Expense0000
Other Income / Expenses41K19.58M14.96M16.92M
Income Before Tax(23.87M)(20.54M)(62.81M)(143.44M)
Pre-Tax Margin-1969.3%-862.9%-2650.0%-5026.0%
Income Tax Expense0000
Net Income(23.87M)(20.54M)(62.81M)(143.44M)
Net Margin-1969.3%-862.9%-2650.0%-5026.0%
EPS (Basic)(0.66)(1.05)(1.49)(2.66)
EPS (Diluted)(0.66)(1.05)(1.49)(2.66)
Weighted Avg Shares36.32M36.32M51.34M53.85M
Weighted Avg Shares (Diluted)36.32M36.32M51.34M53.85M

Upstream Bio, Inc.

NASDAQ:UPB

Intrinsic Alpha fair value

Locked

Current Price

$2.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.